Glaukos (GKOS) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $164.84, -0.46% vs the prior close of $165.60.
- Volume 985.42K shares, 1.2x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
GKOS dips 0.5% to $164.84. Closed at $164.84, -0.46% vs the prior close of $165.60. Day range $163.13–$167.27, opened at $166.08.
GKOS daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — GKOS dips 0.5% to $164.84
- Closed at $164.84, -0.46% vs the prior close of $165.60. Day range $163.13–$167.27, opened at $166.08.
- Volume was 985.42K shares, 1.2x its 50-day average of 816.07K.
- Price is -4.4% vs its 50-day average ($172.38) and +19.8% vs its 200-day average ($137.56).
- 52-week range $73.16–$191.62; today's close sits at 77% of that range, 14.0% below the 52-week high.
Oct 15, 2026 — GKOS dips 1.4% to $165.60
- Closed at $165.60, -1.36% vs the prior close of $167.89. Day range $165.36–$170.20, opened at $168.26.
- Volume was 778.60K shares, 1.0x its 50-day average of 814.61K.
- Price is -4.0% vs its 50-day average ($172.50) and +20.6% vs its 200-day average ($137.30).
- 52-week range $73.16–$191.62; today's close sits at 78% of that range, 13.6% below the 52-week high.
Oct 14, 2026 — GKOS rises 1.4% to $167.89
- Closed at $167.89, +1.44% vs the prior close of $165.50. Day range $164.89–$168.36, opened at $164.94.
- Volume was 624.10K shares, 0.8x its 50-day average of 818.12K.
- Price is -2.7% vs its 50-day average ($172.61) and +22.5% vs its 200-day average ($137.05).
- 52-week range $73.16–$191.62; today's close sits at 80% of that range, 12.4% below the 52-week high.
Oct 13, 2026 — GKOS dips 1.5% to $165.50
- Closed at $165.50, -1.50% vs the prior close of $168.02. Day range $164.95–$171.22, opened at $169.53.
- Volume was 909.90K shares, 1.1x its 50-day average of 822.10K.
- Price is -4.1% vs its 50-day average ($172.66) and +21.0% vs its 200-day average ($136.80).
- 52-week range $73.16–$191.62; today's close sits at 78% of that range, 13.6% below the 52-week high.
Oct 12, 2026 — GKOS rises 1.4% to $168.02
- Closed at $168.02, +1.41% vs the prior close of $165.69. Day range $162.97–$171.42, opened at $166.79.
- Volume was 881.90K shares, 1.1x its 50-day average of 825.10K.
- Price is -2.8% vs its 50-day average ($172.77) and +23.0% vs its 200-day average ($136.55).
- 52-week range $73.16–$191.62; today's close sits at 80% of that range, 12.3% below the 52-week high.
Oct 9, 2026 — GKOS rises 2.7% to $165.69
- Closed at $165.69, +2.73% vs the prior close of $161.29. Day range $159.89–$166.97, opened at $160.06.
- Volume was 1.20M shares, 1.4x its 50-day average of 852.38K.
- Price is -4.1% vs its 50-day average ($172.75) and +21.6% vs its 200-day average ($136.29).
- 52-week range $73.16–$191.62; today's close sits at 78% of that range, 13.5% below the 52-week high.
Oct 8, 2026 — GKOS slides 6.3% to $161.29 on 3.4x normal volume
- Closed at $161.29, -6.32% vs the prior close of $172.18. Day range $146.38–$170.86, opened at $170.67.
- Volume was 2.90M shares, 3.4x its 50-day average of 857.13K — unusually heavy trading.
- Price is -6.7% vs its 50-day average ($172.80) and +18.6% vs its 200-day average ($136.05).
- 52-week range $73.16–$191.62; today's close sits at 74% of that range, 15.8% below the 52-week high.
Oct 7, 2026 — GKOS jumps 6.6% to $172.18
- Closed at $172.18, +6.55% vs the prior close of $161.59. Day range $159.59–$174.48, opened at $161.00.
- Volume was 1.49M shares, 1.7x its 50-day average of 850.27K.
- Price is -0.4% vs its 50-day average ($172.81) and +26.8% vs its 200-day average ($135.82).
- 52-week range $73.16–$191.62; today's close sits at 84% of that range, 10.1% below the 52-week high.
Oct 6, 2026 — GKOS dips 1.5% to $161.59
- Closed at $161.59, -1.48% vs the prior close of $164.01. Day range $160.30–$164.00, opened at $163.84.
- Volume was 664.40K shares, 0.8x its 50-day average of 851.53K.
- Price is -6.3% vs its 50-day average ($172.39) and +19.2% vs its 200-day average ($135.53).
- 52-week range $73.16–$191.62; today's close sits at 75% of that range, 15.7% below the 52-week high.
Oct 5, 2026 — GKOS ends flat (+0.2%) to $164.01
- Closed at $164.01, +0.16% vs the prior close of $163.75. Day range $163.17–$165.99, opened at $164.44.
- Volume was 837.80K shares, 1.0x its 50-day average of 842.37K.
- Price is -4.8% vs its 50-day average ($172.20) and +21.2% vs its 200-day average ($135.28).
- 52-week range $73.16–$191.62; today's close sits at 77% of that range, 14.4% below the 52-week high.
Oct 2, 2026 — GKOS rises 0.4% to $163.75
- Closed at $163.75, +0.36% vs the prior close of $163.17. Day range $163.01–$168.08, opened at $167.57.
- Volume was 742.80K shares, 0.9x its 50-day average of 835.93K.
- Price is -4.8% vs its 50-day average ($171.99) and +21.3% vs its 200-day average ($135.03).
- 52-week range $73.16–$191.62; today's close sits at 76% of that range, 14.5% below the 52-week high.
GKOS latest news & SEC filings
Every SEC filing by or about GKOS in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Navratil Tomas sold 888 shares at $163.93 (≈$145.57K) on Oct 5, 2026; now holds 69,930
- Navratil Tomas sold 327 shares at $164.78 (≈$53.88K) on Oct 5, 2026; now holds 69,603
- Navratil Tomas sold 312 shares at $165.60 (≈$51.67K) on Oct 5, 2026; now holds 69,291
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 5, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 28, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Navratil Tomas sold 167 shares at $151.70 (≈$25.33K) on Sep 25, 2026; now holds 72,266
- Navratil Tomas sold 136 shares at $152.71 (≈$20.77K) on Sep 25, 2026; now holds 72,130
- Navratil Tomas sold 229 shares at $154.24 (≈$35.32K) on Sep 25, 2026; now holds 71,901
- Navratil Tomas sold 1,083 shares at $154.88 (≈$167.74K) on Sep 25, 2026; now holds 70,818
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 25, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Navratil Tomas sold 103 shares at $163.20 (≈$16.81K) on Sep 16, 2026; now holds 73,787
- Navratil Tomas sold 345 shares at $164.60 (≈$56.79K) on Sep 16, 2026; now holds 73,442
- Navratil Tomas sold 191 shares at $166.20 (≈$31.74K) on Sep 16, 2026; now holds 73,251
- Navratil Tomas sold 460 shares at $167.32 (≈$76.97K) on Sep 16, 2026; now holds 72,791
- Navratil Tomas sold 120 shares at $168.38 (≈$20.21K) on Sep 16, 2026; now holds 72,671
- Navratil Tomas sold 234 shares at $170.95 (≈$40.00K) on Sep 16, 2026; now holds 72,437
- …plus 1 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 16, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 3, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jul 29, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $185.61M (prior year $124.12M) (+49.5% vs Jun 30, 2025)
- Net income: -$18.38M (prior year -$19.66M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.31 (prior year -$0.34) (loss narrowed vs Jun 30, 2025)
Jul 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade GKOS
- Last results release: Jul 29, 2026 (8-K Item 2.02). Previous ones: Apr 29, 2026, Feb 17, 2026, Jan 13, 2026. Based on that rhythm, the next report is likely around Oct 28, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.91% (largest 6.6%).
- Liquidity: about 1.02M shares (≈$168.15M) trade per day on average.
- 52-week position: $164.84 vs a range of $73.16–$191.62 (77% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Tomas Navratil sold 167 shares on Sep 25, 2026.
- Latest filings: 8-K Aug 3, 2026; 10-Q Jul 29, 2026; 8-K Jul 29, 2026.
- Share count: 58.98M shares outstanding (Jul 28, 2026), +2.8% vs a year earlier.
- Listing: NYSE · industry: Surgical & Medical Instruments & Apparatus.
GKOS market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 166.08 | 167.27 | 163.13 | 164.84 | 985.42K |
| Oct 15, 2026 | 168.26 | 170.20 | 165.36 | 165.60 | 778.60K |
| Oct 14, 2026 | 164.94 | 168.36 | 164.89 | 167.89 | 624.10K |
| Oct 13, 2026 | 169.53 | 171.22 | 164.95 | 165.50 | 909.90K |
| Oct 12, 2026 | 166.79 | 171.42 | 162.97 | 168.02 | 881.90K |
| Oct 9, 2026 | 160.06 | 166.97 | 159.89 | 165.69 | 1.20M |
| Oct 8, 2026 | 170.67 | 170.86 | 146.38 | 161.29 | 2.90M |
| Oct 7, 2026 | 161.00 | 174.48 | 159.59 | 172.18 | 1.49M |
| Oct 6, 2026 | 163.84 | 164.00 | 160.30 | 161.59 | 664.40K |
| Oct 5, 2026 | 164.44 | 165.99 | 163.17 | 164.01 | 837.80K |
| Oct 2, 2026 | 167.57 | 168.08 | 163.01 | 163.75 | 742.80K |
| Oct 1, 2026 | 164.00 | 168.73 | 162.08 | 163.17 | 808.40K |
| Sep 30, 2026 | 158.31 | 165.65 | 157.29 | 164.19 | 947.00K |
| Sep 29, 2026 | 153.56 | 159.06 | 152.39 | 158.55 | 638.20K |
| Sep 28, 2026 | 153.11 | 160.98 | 151.71 | 158.56 | 1.40M |
| Sep 25, 2026 | 154.50 | 155.60 | 151.01 | 154.43 | 826.20K |
| Sep 24, 2026 | 153.70 | 156.65 | 152.75 | 154.88 | 838.40K |
| Sep 23, 2026 | 159.86 | 162.04 | 153.31 | 153.49 | 1.03M |
| Sep 22, 2026 | 165.36 | 165.36 | 159.00 | 159.86 | 1.10M |
| Sep 21, 2026 | 166.27 | 166.74 | 160.23 | 161.53 | 806.50K |
About Glaukos
Glaukos (GKOS) is listed on the NYSE and classified by the SEC under “Surgical & Medical Instruments & Apparatus”. Its business address is in ALISO VIEJO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1192448.
GKOS board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Thomas William Burns | CHAIRMAN & CEO | Jun 29, 2026 |
| Mark J Foley | Director | Jun 23, 2026 |
| David F Hoffmeister | Director | Jun 23, 2026 |
| Gilbert H Kliman | Director | Aug 20, 2026 |
| Marc Stapley | Director | Jun 23, 2026 |
| Denice Torres | Director | Jun 23, 2026 |
| Aimee S Weisner | Director | Jun 23, 2026 |
| Leana Wen | Director | Aug 3, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Thomas William Burns | CHAIRMAN & CEO | Jun 29, 2026 |
| Joseph E Gilliam | PRESIDENT & COO | Aug 13, 2026 |
| Tomas Navratil | CHIEF DEVELOPMENT OFFICER | Sep 28, 2026 |
| Alex R. Thurman | SVP & CHIEF FINANCIAL OFFICER | Aug 11, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 25, 2026 | Tomas Navratil | Sale | 167 | $151.70 |
| Sep 25, 2026 | Tomas Navratil | Sale | 136 | $152.71 |
| Sep 25, 2026 | Tomas Navratil | Sale | 229 | $154.24 |
| Sep 25, 2026 | Tomas Navratil | Sale | 1,083 | $154.88 |
| Sep 25, 2026 | Tomas Navratil | Sale | 167 | $151.70 |
| Sep 25, 2026 | Tomas Navratil | Sale | 136 | $152.71 |
| Sep 25, 2026 | Tomas Navratil | Sale | 229 | $154.24 |
| Sep 25, 2026 | Tomas Navratil | Sale | 1,083 | $154.88 |
| Sep 25, 2026 | Tomas Navratil | Sale | 167 | $151.70 |
| Sep 25, 2026 | Tomas Navratil | Sale | 136 | $152.71 |
| Sep 25, 2026 | Tomas Navratil | Sale | 229 | $154.24 |
| Sep 25, 2026 | Tomas Navratil | Sale | 1,083 | $154.88 |
| Sep 25, 2026 | Tomas Navratil | Sale | 167 | $151.70 |
| Sep 25, 2026 | Tomas Navratil | Sale | 136 | $152.71 |
| Sep 25, 2026 | Tomas Navratil | Sale | 229 | $154.24 |
GKOS financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $507.44M | $-187.69M | -3.28 | $-14.79M |
| Dec 31, 2024 | $383.48M | $-146.37M | -2.77 | $-61.32M |
| Dec 31, 2023 | $314.71M | $-134.66M | -2.78 | $-57.76M |
| Dec 31, 2022 | $282.86M | $-99.19M | -2.09 | $-33.08M |
| Dec 31, 2021 | $294.01M | $-49.59M | -1.07 | $24.71M |
Latest balance sheet: total assets $920.52M, total liabilities $238.03M, cash $114.48M (as of Jun 30, 2026).
GKOS earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 29, 2026 | 8-K Item 2.02 (results) | $161.66 |
| Apr 29, 2026 | 8-K Item 2.02 (results) | $116.96 |
| Feb 17, 2026 | 8-K Item 2.02 (results) | $106.64 |
| Jan 13, 2026 | 8-K Item 2.02 (results) | $110.23 |
| Oct 29, 2025 | 8-K Item 2.02 (results) | $77.09 |
| Jul 30, 2025 | 8-K Item 2.02 (results) | $94.05 |
| Apr 30, 2025 | 8-K Item 2.02 (results) | $94.25 |
| Feb 20, 2025 | 8-K Item 2.02 (results) | $157.36 |
| Nov 4, 2024 | 8-K Item 2.02 (results) | $131.38 |
| Jul 31, 2024 | 8-K Item 2.02 (results) | — |
| May 1, 2024 | 8-K Item 2.02 (results) | — |
| Feb 21, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Surgical & Medical Instruments & Apparatus
Boston Scientific (BSX)Stryker (SYK)3M (MMM)Dexcom (DXCM)Medline (MDLN)Becton Dickinson (BDX)MiniMed (MMED)Resmed (RMD)Insulet (PODD)West Pharmaceutical Services (WST)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on GKOS
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.